Bevacizumab

Bevacizumab promising for advanced cervical cancer

By

Research has revealed that women with advanced cervical cancer live about 4 months longer with the combined use of bevacizumab and chemotherapy compared with chemotherapy alone.

Adjuvant bevacizumab increases cervical cancer survival

Adjuvant bevacizumab increases cervical cancer survival

Adjuvant bevacizumab increases overall survival in cervical cancer, and two studies show benefits of bevacizumab on PFS in newly diagnosed glioblastoma as well.

Bevacizumab promising in locally advanced cervical cancer

By

A phase 2 trial of bevacizumab in addition to cisplatin and pelvic radiation for locally advanced cervical cancer found that adding bevacizumab to the existing standard of care showed promising overall results.

Resistance mechanism of colorectal cancer to bevacizumab detailed

By

When colorectal cancer is targeted by the drug bevacizumab, tumors may switch dependence from VEGF-A (targeted by the drug) to related growth factors that include VEGF-C, VEGF-D, and placental growth factor.

Brain cancer survival is improved with bevacizumab

By

A new study has found that patients with glioblastoma who died in 2010, after the FDA approved bevacizumab for the treatment of the deadly brain cancer, had lived significantly longer than patients who died prior to the conditional approval of the drug for this indication.

Test identifies which patients with glioblastoma are most likely to benefit from bevacizumab

By

A new test may help identify which patients with newly diagnosed glioblastoma are more likely to benefit from bevacizumab.

Bevacizumab added to initial glioblastoma treatment does not extend lives

By

Adding bevacizumab to initial treatment for glioblastoma did not improve overall patient survival or progression-free survival, according to results of a randomized phase III trial.

Time to tumor growth best predicts survival in colorectal cancer

Time to tumor growth proved to be the best metric for predicting overall survival in persons with metastatic colorectal cancer on bevacizumab.

CT data help predict survival in metastatic melanoma

Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab.

Dasatinib thwarts brain cancer metastasis after bevacizumab use

Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.

Bevacizumab prolongs life in ongoing trial of cervical cancer

Bevacizumab plus chemotherapy improved survival in women with advanced, recurrent, or persistent cervical cancer, according to interim findings.

Bevacizumab approved in combination therapy for metastatic colorectal cancer

The FDA has approved bevacizumab combined with other chemotherapy when metastatic colorectal cancer has progressed after first-line bevacizumab.

SABCS: Bevacizumab No Help in Triple-Negative Breast Cancer

SABCS: Bevacizumab No Help in Triple-Negative Breast Cancer

No significant improvement in invasive disease-free survival with bevacizumab plus chemo, according to a study.

Noninvasive technique predicts patients' response to chemotherapy

By

Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.

Noninvasive technique predicts patients' response to chemotherapy

By

Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.

Protein levels may predict if patients with colorectal cancer patients benefit from bevacizumab

By

Patients with low levels of the protein VEGF165b who were treated with bevacizumab (Avastin) survived 3 months longer without their colorectal cancer progressing compared with patients not treated with the drug.

Radiosensitivity: A new focus on cardiovascular sequelae

Radiosensitivity: A new focus on cardiovascular sequelae

By

An increased risk of coronary artery stenosis in cancer survivors may be a long-term posttreatment effect of chest radiotherapy.

VEGF blockade: Optimizing chemotherapy drug uptake

VEGF blockade: Optimizing chemotherapy drug uptake

By

New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.

Bevacizumab delays return of ovarian cancer

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.

LATE-BREAKING NEWS: FDA revokes Avastin breast cancer indication

The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.

Bevacizumab label now warns of ovarian, osteonecrosis risks

The FDA has announced labeling changes for bevacizumab (Avastin), indicated for the treatment of glioblastoma and colorectal, breast, kidney, and nonsquamous non-small cell lung cancers.

Oncology Nurse Advisor Forum - March/April 2011

The Advisor Forum panel answers nurses' questions about patient care, treatment regimens, and oncology nursing.

Update affirms breast cancer treatment guidelines

The Clinical Practice Guide­lines in Oncology for Breast Cancer, published by NCCN, have been updated to affirm the existing recommendation regarding the use of bevacizumab (Avastin) for the treatment of metastatic breast cancer.

Risk of venous thromboembolism

Treating patients with the recombinant monoclonal antibody bevacizumab carries a significant risk of venous thromboembolism (VTE), a meta-analysis has shown.

Combination therapy in metastatic CRC

Adding cetuximab to the treatment regimen of patients with metastatic colorectal cancer (CRC) results in worse outcomes, a controlled trial has shown.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs